Interactive Financial Charts Not Available

Incyte (INCY) | Financial Analysis & Statements

Incyte Corporation | Large-cap | Healthcare

$78.39

0.24%

Incyte vs Vertex Incyte vs Regeneron Incyte vs Alnylam Incyte vs Insmed Incyte vs Royalty Pharma plc Incyte vs S&P 500 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 1.1B

Gross Profit 979.7M 93.05%

Operating Income 216.7M 20.58%

Net Income 158.2M 15.03%

EPS (Diluted) $0.80

Balance Sheet Metrics

Total Assets 5.7B

Total Liabilities 2.1B

Shareholders Equity 3.7B

Debt to Equity 0.57

Cash Flow Metrics

Operating Cash Flow 251.9M

Free Cash Flow 262.9M

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Incyte Income Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Revenue i	4.2B	3.7B	3.4B	3.0B	2.7B
Cost of Goods Sold i	312.1M	255.0M	207.0M	151.0M	131.3M
Gross Profit i	3.9B	3.4B	3.2B	2.8B	2.5B
Gross Margin % i	92.6%	93.1%	93.9%	94.9%	95.1%
Operating Expenses
Research & Development i	2.6B	1.6B	1.6B	1.5B	2.2B
Selling, General & Administrative i	1.2B	1.2B	1.0B	739.6M	516.9M
Other Operating Expenses i	-1.0M	2.0M	8.0M	37.0M	42.8M
Total Operating Expenses i	3.8B	2.8B	2.6B	2.2B	2.8B
Operating Income i	101.3M	649.7M	591.6M	600.5M	-240.2M
Operating Margin % i	2.4%	17.6%	17.4%	20.1%	-9.0%
Non-Operating Items
Interest Income i	128.7M	172.3M	39.9M	10.6M	-
Interest Expense i	2.3M	2.6M	2.7M	1.9M	2.2M
Other Non-Operating Income	88.8M	14.7M	-99.7M	-38.8M	10.2M
Pre-tax Income i	316.6M	834.2M	529.1M	570.4M	-232.2M
Income Tax i	284.0M	236.6M	188.5M	-378.1M	63.5M
Effective Tax Rate % i	89.7%	28.4%	35.6%	-66.3%	0.0%
Net Income i	32.6M	597.6M	340.7M	948.6M	-295.7M
Net Margin % i	0.8%	16.2%	10.0%	31.8%	-11.1%
Key Metrics
EBITDA i	332.1M	904.7M	699.4M	669.0M	-165.3M
EPS (Basic) i	$0.16	$2.67	$1.53	$4.30	$-1.36
EPS (Diluted) i	$0.15	$2.65	$1.52	$4.27	$-1.36
Basic Shares Outstanding i	207110000	223628000	222004000	220428000	218073000
Diluted Shares Outstanding i	207110000	223628000	222004000	220428000	218073000

Income Statement Trend

Incyte Balance Sheet From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Assets
Current Assets
Cash & Equivalents i	1.7B	3.2B	3.0B	2.1B	1.5B
Short-term Investments i	470.3M	442.7M	287.5M	290.8M	288.4M
Accounts Receivable i	853.2M	743.6M	644.9M	616.3M	482.0M
Inventory i	58.9M	63.0M	42.0M	27.9M	16.4M
Other Current Assets	168.9M	182.8M	167.0M	126.3M	60.1M
Total Current Assets i	3.2B	4.6B	4.1B	3.1B	2.4B
Non-Current Assets
Property, Plant & Equipment i	282.8M	266.8M	241.8M	159.9M	141.3M
Goodwill i	425.0M	434.7M	440.4M	461.9M	483.5M
Intangible Assets i	113.8M	123.5M	129.2M	150.8M	172.3M
Long-term Investments	-	-	-	-	-
Other Non-Current Assets	1.1B	892.8M	564.0M	535.6M	62.8M
Total Non-Current Assets i	2.2B	2.1B	1.7B	1.8B	1.2B
Total Assets i	5.4B	6.8B	5.8B	4.9B	3.6B
Liabilities
Current Liabilities
Accounts Payable i	197.5M	109.6M	277.5M	172.1M	98.8M
Short-term Debt i	10.0M	9.1M	11.4M	13.2M	15.0M
Current Portion of Long-term Debt	-	-	-	-	-
Other Current Liabilities	98.1M	111.7M	105.0M	82.8M	73.5M
Total Current Liabilities i	1.6B	1.2B	1.2B	854.3M	631.2M
Non-Current Liabilities
Long-term Debt i	33.5M	29.2M	30.1M	31.6M	32.6M
Deferred Tax Liabilities i	-	-	-	-	-
Other Non-Current Liabilities	321.3M	322.7M	283.7M	277.4M	285.9M
Total Non-Current Liabilities i	354.8M	351.9M	313.8M	309.0M	318.5M
Total Liabilities i	2.0B	1.6B	1.5B	1.2B	949.6M
Equity
Common Stock i	193.0K	224.0K	223.0K	221.0K	219.0K
Retained Earnings i	-1.1B	160.4M	-437.2M	-777.9M	-1.7B
Treasury Stock i	-	-	-	-	-
Other Equity	-	-	-	-	-
Total Shareholders Equity i	3.4B	5.2B	4.4B	3.8B	2.6B
Key Metrics
Total Debt i	43.5M	38.3M	41.5M	44.8M	47.5M
Working Capital i	1.6B	3.4B	2.9B	2.3B	1.7B

Balance Sheet Composition

Incyte Cash Flow Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income i	32.6M	597.6M	340.7M	948.6M	-295.7M
Depreciation & Amortization i	89.2M	82.7M	67.9M	57.8M	51.8M
Stock-Based Compensation i	266.1M	215.9M	188.4M	183.0M	177.9M
Working Capital Changes i	-151.1M	-436.8M	9.4M	-81.9M	-177.5M
Operating Cash Flow i	162.1M	352.3M	692.9M	658.1M	-220.0M
Investing Activities
Capital Expenditures i	-	-	-	-	-
Acquisitions i	-	-	-	-	-
Investment Purchases i	-258.4M	-466.0M	-79.9M	-268.7M	-612.3M
Investment Sales i	516.0M	305.8M	79.2M	242.0M	530.7M
Investing Cash Flow i	257.7M	-160.2M	-709.0K	-26.7M	-81.6M
Financing Activities
Share Repurchases i	-2.0B	-	-	-	-
Dividends Paid i	-	-	-	-	-
Debt Issuance i	-	-	-	-	-
Debt Repayment i	-3.8M	-3.4M	-2.9M	-2.4M	-836.0K
Financing Cash Flow i	-2.1B	-55.9M	-61.9M	-52.4M	-61.4M
Free Cash Flow i	235.2M	449.0M	892.1M	568.5M	-312.0M
Net Change in Cash i	-1.7B	136.2M	630.3M	578.9M	-362.9M

Cash Flow Trend

Incyte Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 18.53

Forward P/E 12.77

Price to Book 3.65

Price to Sales 3.34

PEG Ratio 12.77

Profitability Ratios

Profit Margin 18.99%

Operating Margin 25.63%

Return on Equity 24.30%

Return on Assets 11.52%

Financial Health

Current Ratio 2.85

Debt to Equity 1.02

Beta 0.72

Per Share Data

EPS (TTM) $4.23

Book Value per Share $21.49

Revenue per Share $23.71

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
incy	15.3B	18.53	3.65	24.30%	18.99%	1.02
Vertex	94.0B	26.03	5.47	22.77%	31.86%	8.89
Regeneron	59.7B	14.18	1.96	15.34%	31.37%	9.04
Alnylam	57.5B	-201.34	229.45	-257.83%	-12.96%	1,093.31
Insmed	23.2B	-19.67	18.51	-160.54%	-259.82%	59.14
Royalty Pharma plc	21.9B	16.41	2.56	17.29%	44.28%	84.40

Financial data is updated regularly. All figures are in the company's reporting currency.